Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
RELATED PRODUCTS
-
123I MIBG BACON (R&D)
123I MIBG BACON (R&D)It is indicated for: Oncology: a) Scintigraphic localization of tumors originating in tissues that derive embryologically from the neural crest... -
IODOSOL 123I (R&D)
IODOSOL 123I (R&D)Sodium iodide (123I) solution is indicated as a diagnostic agent to evaluate thyroid function and/or morphology by scintigraphy and radioactive iodine uptake test. -
PARTITION FLASK
PARTITION FLASKVial containing a mixture of solvents to carry out a chromatographic separation ... -
PSMA (R+D)
PSMA (R+D)It is indicated for the detection and evaluation of prostate cancer from the initial diagnosis to the monitoring of castration-resistant metastases. -
AV45 (R+D)
AV45 (R+D)It is indicated for estimating the density of β-amyloid neuritic plaque in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive...